PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30237856-7 2018 We also found that elevating glucosylceramide levels in flu-resistant clonal cells was associated with up-regulation of GCS and CD34 expression. fludarabine 56-59 CD34 molecule Homo sapiens 128-132 30237856-4 2018 By comparing parental MEC-2 cells, a human CLL cell line, we found that flu-resistant clonal cells were significantly increased lethal dose 50 of flu concentration, and up-regulated expression of P-glycoprotein, a drug-resistant marker, glucosylceramide synthase (GCS), an enzyme that can convert ceramide to glucosylceramide, and CD34, a leukemia stem cell marker. fludarabine 72-75 CD34 molecule Homo sapiens 331-335 30237856-8 2018 Importantly, overexpression of GCS or CD34 was also determined in flu-refractory PBMCs. fludarabine 66-69 CD34 molecule Homo sapiens 38-42 10980639-2 2000 DESIGN AND METHODS: We describe a 49-year old patient who developed a III stage IgD k MM after fludarabine treatment for a previous diagnosis of CLL and then was submitted to an high-dose treatment with autologous CD34+ selected stem cell support. fludarabine 95-106 CD34 molecule Homo sapiens 214-218 29555312-10 2018 We conclude that a CD34+ selected stem cell boost can be considered for treatment of mixed chimerism after alemtuzumab, fludarabine, and melphalan RIC HSCT in children and young adults with primary immune deficiencies. fludarabine 120-131 CD34 molecule Homo sapiens 19-23 20208572-0 2010 CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies. fludarabine 146-157 CD34 molecule Homo sapiens 0-4 15158086-8 2004 More significantly, ajoene profoundly enhanced the apoptotic effect of the two chemotherapeutic drugs: cytarabine and fludarabine in human CD34-positive resistant myeloid leukaemia cells through enhancing their bcl-2 inhibitory and caspase-3 activation activities. fludarabine 118-129 CD34 molecule Homo sapiens 139-143 14586480-0 2004 Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. fludarabine 127-138 CD34 molecule Homo sapiens 11-15 10759719-4 2000 In univariate and multivariate analyses, the numbers of cells collected were not significantly influenced by the nature of mobilizing regimen and there was a trend towards the collection of a higher number of CD34+ cells from patients who received fludarabine only before mobilization. fludarabine 248-259 CD34 molecule Homo sapiens 209-213 10759719-5 2000 There was a significant correlation between the median number of CD34+ cells collected and the number of courses of fludarabine (higher CD34+ cell numbers were related to more than six courses) and the interval between the last dose of fludarabine and the start of mobilizing therapy (higher CD34+ cell numbers were related to a delay > or = 2 months). fludarabine 116-127 CD34 molecule Homo sapiens 65-69 10759719-5 2000 There was a significant correlation between the median number of CD34+ cells collected and the number of courses of fludarabine (higher CD34+ cell numbers were related to more than six courses) and the interval between the last dose of fludarabine and the start of mobilizing therapy (higher CD34+ cell numbers were related to a delay > or = 2 months). fludarabine 116-127 CD34 molecule Homo sapiens 136-140 10759719-5 2000 There was a significant correlation between the median number of CD34+ cells collected and the number of courses of fludarabine (higher CD34+ cell numbers were related to more than six courses) and the interval between the last dose of fludarabine and the start of mobilizing therapy (higher CD34+ cell numbers were related to a delay > or = 2 months). fludarabine 116-127 CD34 molecule Homo sapiens 136-140 10759719-5 2000 There was a significant correlation between the median number of CD34+ cells collected and the number of courses of fludarabine (higher CD34+ cell numbers were related to more than six courses) and the interval between the last dose of fludarabine and the start of mobilizing therapy (higher CD34+ cell numbers were related to a delay > or = 2 months). fludarabine 236-247 CD34 molecule Homo sapiens 65-69 10023011-5 1999 The IC50 of cytarabine and fludarabine were significantly higher in CD34 positive cells with high Bcl-2 than in CD34 negative cells with low Bcl-2. fludarabine 27-38 CD34 molecule Homo sapiens 68-72 10456672-7 1999 Both cytarabine and fludarabine induced a dose dependent increase in the number of apoptotic cells in both CD34 positive cell types. fludarabine 20-31 CD34 molecule Homo sapiens 107-111 10456672-12 1999 Using a quantitative ELISA assay, the Bcl-2 protein concentration was reduced by 86 or 100%, after 72 h of treatment with 10 microM cytarabine or fludarabine, respectively, in both CD34 positive leukaemia cell types. fludarabine 146-157 CD34 molecule Homo sapiens 181-185 10023011-5 1999 The IC50 of cytarabine and fludarabine were significantly higher in CD34 positive cells with high Bcl-2 than in CD34 negative cells with low Bcl-2. fludarabine 27-38 CD34 molecule Homo sapiens 112-116 9688287-5 1998 The number of circulating CD34+ cells/l of PB was significantly lower in patients treated with fludarabine or chlorambucil compared to untreated patients. fludarabine 95-106 CD34 molecule Homo sapiens 26-30 9688287-8 1998 Three-colour fluorescence analysis demonstrated a differentiation pattern of CD34+ cells, with a greater expression of CD13 and CD33 after treatment with fludarabine compared to untreated patients and normal controls. fludarabine 154-165 CD34 molecule Homo sapiens 77-81 9688287-9 1998 In 4 patients previously treated with fludarabine who underwent a successful cyclophosphamide and G-CSF mobilization therapy, 4x10(6) CD34+ cells/kg were collected. fludarabine 38-49 CD34 molecule Homo sapiens 134-138